Filing identity and business context
The supplied filing is for OXIS International, Inc., not GT Biopharma, Inc. It is a Form 10-Q for the quarter ended March 31, 2014—not 2013 Q3 as stated in the request metadata. The filing was signed January 8, 2015. OXIS described its business as developing and selling or licensing nutraceutical, personal-care, functional-food, veterinary, and potential pharmaceutical products, with a primary focus on ergothioneine (ERGO). The filing also discusses a planned cannabinoid-focused subsidiary.
Financial performance and position
| Metric | Quarter ended March 31, 2014 | Comparable 2013 period / balance-sheet context |
|---|---|---|
| Revenue | $0 | $88,000 |
| Gross profit | $0 | $19,000 |
| Operating expenses | $101,000, all selling, general and administrative | $366,000; no research and development expense in either period |
| Operating loss | $101,000 | $347,000 |
| Interest expense | $197,000 | $531,000 |
| Net income (loss) | $(371,000) | $468,000 |
| Cash flow from operations | $(90,000) | $(138,000) |
| Cash and cash equivalents | $4,000 at March 31, 2014 | $43,000 at December 31, 2013; cash-flow statement reports $0 at March 31, 2013 |
| Total assets / total liabilities | $103,000 / $6.808 million | $147,000 / $6.481 million at December 31, 2013 |
| Accumulated deficit / stockholders’ deficit | $89.838 million / $6.705 million | At March 31, 2014 |
Margins were not meaningful in 2014 because there was no revenue. Current liabilities were $6.680 million, including $214,000 of warrant liability; management described $6.466 million as current cash obligations. The company reported a working-capital deficit of approximately $6.603 million. Financing activities provided $50,000 in the quarter, but cash fell by $39,000 to $4,000.
Changes, outlook, risks, and unusual items
- Revenue fell by $88,000 year over year, while SG&A declined by $265,000, primarily due to lower professional fees and the absence of the prior-year stock-option vesting expense.
- The 2013 quarterly profit was driven primarily by a $1.360 million gain from changes in the fair value of warrant and derivative liabilities. In 2014, the comparable fair-value change was a $72,000 loss. This non-operating swing explains why the lower operating loss did not translate into improved net income.
- Management stated that the company’s cash usage raised substantial doubt about its ability to continue as a going concern. It planned to seek additional equity or debt financing and grow product revenue, but gave no assurance that financing or commercial revenue would be sufficient.
- The filing reports substantial outstanding debt, including overdue obligations and convertible instruments, as well as 598.2 million outstanding warrants at a weighted-average exercise price of $0.01 and 29.3 million options. Potential conversion and exercise may create significant dilution. The company had 573.1 million common shares outstanding at March 31, 2014.
- After quarter-end, the company disclosed additional financing transactions, including convertible debentures and warrants; these are subsequent events, not March-quarter operating results. The filing also describes an October 2014 resolution of a licensing dispute in exchange for cash and a perpetual royalty on future product sales; the amount is not stated in the supplied text.
- Management concluded that disclosure controls and internal control over financial reporting were ineffective at March 31, 2014, citing inadequate segregation of duties, reliance on outside consultants, and risks of executive override.
Most important facts to verify
- Confirm the requested issuer and period: the supplied document identifies OXIS International and the quarter ended March 31, 2014.
- Verify the company’s ability to secure near-term funding, meet current obligations, and continue as a going concern.
- Review debt maturities, defaults, conversion terms, collateral rights, and the potential dilution from outstanding securities.
- Assess whether planned ERGO products and the cannabinoid program can generate commercial revenue; the filing provides no specific revenue guidance.
- Check the outcome and financial terms of the licensing dispute settlement and the status of the identified internal-control weaknesses.